{
  "138-1.xlsx": {
    "中科新生命科研、临床蛋白质组学": [
      -1.0,
      -1.0,
      -1.0,
      -1.0
    ],
    "华大基因科研、临床基因组（含蛋白质组）": [
      316133.37,
      60589.99,
      676613.73,
      146153.63
    ],
    "诺禾致源科研基因组（含蛋白质组）": [
      84972.06,
      5669.66,
      186639.63,
      22498.61
    ],
    "欧易生物科研蛋白质组": [
      -1.0,
      -1.0,
      -1.0,
      -1.0
    ],
    "title": [
      "2022年1-6月营业收入 （万元）",
      "2022年1-6月归属于母公司所有者的 净利润 （万元）",
      "2021年营业收入（万元）",
      "2021年归属于母公司所有者的净利润 （万元）"
    ]
  },
  "140-1.xlsx": {
    "Abcam科研": [
      -1.0,
      -1.0,
      -1.0,
      -1.0
    ],
    "CST科研": [
      -1.0,
      -1.0,
      -1.0,
      -1.0
    ],
    "爱博泰克科研、诊断": [
      -1.0,
      -1.0,
      -1.0,
      -1.0
    ],
    "优宁维科研": [
      50262.43,
      4225.85,
      110966.79,
      10872.82
    ],
    "菲鹏生物诊断": [
      -1.0,
      -1.0,
      233189.16,
      147613.13
    ],
    "title": [
      "2022年1-6月营业收入 （万元）",
      "2022年1-6月归属于母公司所有者的净利润（万元）",
      "2021年营业收入（万元）",
      "2021年归属于母公司所有者的净利润（万元）"
    ]
  },
  "146-1.xlsx": {
    "产能（GB）": [
      35100.0,
      68040.0,
      33930.0,
      20430.0
    ],
    "产量（GB）": [
      20713.84,
      46405.73,
      26392.17,
      19289.76
    ],
    "销量（GB）": [
      20752.69,
      45904.42,
      27888.62,
      18496.09
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年",
      "2019年"
    ]
  },
  "147-1.xlsx": {
    "产量": [
      20115173.96,
      18289535.74,
      2089298.62,
      2367338.21
    ],
    "销量": [
      3758690.0,
      2695653.1,
      606555.0,
      473843.6
    ],
    "其中： 对外实现销售": [
      1083830.0,
      2324245.0,
      433770.0,
      218960.0
    ],
    "试用样品赠送": [
      2583900.0,
      143090.0,
      0.0,
      0.0
    ],
    "组学技术服务领用": [
      90960.0,
      228318.1,
      172785.0,
      254883.6
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年",
      "2019年"
    ]
  },
  "148-1.xlsx": {
    "蛋白质组学技术服务": [
      6754.56,
      75.63,
      17137.86,
      77.53,
      14308.07,
      93.22,
      11028.78,
      95.11
    ],
    "蛋白质组分析": [
      3683.44,
      41.24,
      8952.01,
      40.5,
      6459.71,
      42.09,
      5637.92,
      48.62
    ],
    "蛋白质修饰组分析": [
      3071.12,
      34.38,
      8185.85,
      37.03,
      7848.36,
      51.14,
      5390.87,
      46.49
    ],
    "抗体试剂产品": [
      2177.06,
      24.37,
      4966.32,
      22.47,
      1040.18,
      6.78,
      566.52,
      4.89
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例（%）",
      "2021年金额",
      "2021年比例（%）",
      "2020年金额",
      "2020年比例（%）",
      "2019年金额",
      "2019年比例（%）"
    ]
  },
  "148-2_149-1.xlsx": {
    "境内": [
      8764.51,
      98.13,
      21816.9,
      98.7,
      15059.99,
      98.12,
      11416.8,
      98.46
    ],
    "东北": [
      548.41,
      6.14,
      1780.66,
      8.06,
      1046.28,
      6.82,
      848.77,
      7.32
    ],
    "华北": [
      2854.3,
      31.96,
      5899.03,
      26.69,
      3199.23,
      20.84,
      2800.5,
      24.15
    ],
    "华东": [
      2252.32,
      25.22,
      5577.54,
      25.23,
      4016.2,
      26.17,
      2909.64,
      25.09
    ],
    "华南": [
      1227.39,
      13.74,
      2973.96,
      13.45,
      2123.33,
      13.83,
      1175.26,
      10.14
    ],
    "华中": [
      617.33,
      6.91,
      1625.95,
      7.36,
      2143.49,
      13.97,
      1370.8,
      11.82
    ],
    "西北": [
      324.05,
      3.63,
      1391.3,
      6.29,
      721.05,
      4.7,
      775.54,
      6.69
    ],
    "西南": [
      940.71,
      10.53,
      2568.46,
      11.62,
      1810.4,
      11.8,
      1536.29,
      13.25
    ],
    "境外": [
      167.1,
      1.87,
      287.28,
      1.3,
      288.25,
      1.88,
      178.51,
      1.54
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例（%）",
      "2021年度金额",
      "2021年度比例（%）",
      "2020年度金额",
      "2020年度比例（%）",
      "2019年度金额",
      "2019年度比例（%）"
    ]
  },
  "149-2.xlsx": {
    "第一季度": [
      3718.34,
      41.63,
      3223.33,
      14.58,
      1729.24,
      11.27,
      1761.88,
      15.19
    ],
    "第二季度": [
      5213.27,
      58.37,
      4955.47,
      22.42,
      3380.8,
      22.03,
      2497.18,
      21.54
    ],
    "第三季度不适用不适用": [
      5663.82,
      25.62,
      4065.04,
      26.49,
      2621.79,
      22.61
    ],
    "第四季度不适用不适用": [
      8261.56,
      37.38,
      6173.16,
      40.22,
      4714.45,
      40.66
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例 （%）",
      "2021年度金额",
      "2021年度比例 （%）",
      "2020年度金额",
      "2020年度比例 （%）",
      "2019年度金额",
      "2019年度比例 （%）"
    ]
  },
  "150-2_151-1.xlsx": {
    "蛋白质修饰组销量GB": [
      3396.7,
      7387.55,
      4975.43,
      2791.58
    ],
    "分析销售单价元/GB": [
      8828.87,
      10731.23,
      15415.6,
      18571.31
    ],
    "蛋白质组分析销量GB": [
      15252.27,
      35587.23,
      21148.89,
      14801.47
    ],
    "蛋白质组分析销售单价元/GB": [
      2005.63,
      2183.0,
      2522.37,
      3206.35
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年",
      "2019年"
    ]
  },
  "153-1_154-1.xlsx": {
    "TMTsixplex标记试剂用于组学业务中的标记定量盒": [
      0.0,
      23207.08,
      23727.43,
      23420.61
    ],
    "TMT10PLEX标记试剂用于组学业务中的标记定量盒": [
      0.0,
      21338.05,
      26991.15,
      26991.15
    ],
    "固相萃取小柱用于组学业务中的蛋白提取盒（strata-X10mg/1ml）": [
      983.1,
      919.43,
      774.31,
      894.34
    ],
    "胰蛋白酶用于组学业务中的蛋白提取瓶（100ug/ph）": [
      70.8,
      70.8,
      70.8,
      86.21
    ],
    "ExpiFectamine293转染试剂用于抗体业务中的细胞转染实验盒（50次）": [
      0.0,
      6929.13,
      6840.53,
      0.0
    ],
    "Expi293™ExpressionMediu培养基用于抗体业务中的大量表达环节瓶": [
      0.0,
      0.0,
      2443.54,
      2304.11
    ],
    "FectoPRO转染试剂用于抗体业务中的细胞转染实验包（10x1ml）": [
      9151.46,
      11152.24,
      15209.73,
      0.0
    ],
    "超滤离心管通用实验耗材个（0.5ML/10KD）": [
      27.96,
      24.9,
      23.56,
      21.87
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年",
      "2019年"
    ]
  },
  "156-1.xlsx": {
    "电采购数量（万度）": [
      113.66,
      215.93,
      96.82,
      43.14
    ],
    "电采购金额（万元）": [
      117.35,
      214.83,
      131.63,
      59.69
    ],
    "电其中：固定电容费金额（万元）": [
      31.86,
      60.53,
      66.28,
      30.8
    ],
    "电实际用电对应金额（万元）": [
      85.49,
      154.3,
      65.35,
      28.89
    ],
    "电采购单价（不含电容费）（元/度）": [
      0.75,
      0.71,
      0.67,
      0.67
    ],
    "电采购单价（含固定电容费）（元/度）": [
      1.03,
      0.99,
      1.36,
      1.38
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年",
      "2019年"
    ]
  },
  "162-1.xlsx": {
    "12License AgreementThe Board of Trustees of the University of Illinois a body corporate and political of the State of IllinoisPTM Bio LLCSuite 305 2201 West Campell Park Drive Chicago IL约19.94 （215 ft²）2022 年 5 月 1 日-2023年4月30日656.73美元/月办公": [
      0.0
    ],
    "title": [
      "产权证号"
    ]
  },
  "182-1_183-1.xlsx": {
    "1Global profiling of crotonylation on non-histone proteins细胞生物学、蛋白质翻译后修饰Cell Research2017年4月": [
      25.6
    ],
    "2Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma食管癌研究、蛋白质翻译后修饰Signal Transduction and Targeted Therapy2021年11月": [
      18.2
    ],
    "3Dynamic competing histone H4 K5K8 acetylation and butyrylation are hallmarks of highly active gene promoters表观遗传学、蛋白质翻译后修饰Molecular cell2016年4月": [
      17.97
    ],
    "4Chromodomain Protein CDYL Acts as a Crotonyl-CoA Hydratase to Regulate Histone Crotonylation and Spermatogenesis表观遗传学、生殖发育、蛋白质翻译后修饰Molecular Cell2017年9月": [
      17.97
    ],
    "5Acetylation of PHF5A Modulates Stress Responses and Colorectal Carcinogenesis through Alternative Splicing-Mediated Upregulation of KDM3A结肠癌研究、蛋白质翻译后修饰Molecular Cell2019年6月": [
      17.97
    ],
    "6GLP-catalyzed H4K16me1 promotes 53BP1 recruitment to permit DNA damage repair and cell survival表观遗传学、蛋白质翻译后修饰Nucleic Acids Research2019年12月": [
      16.971
    ],
    "7Divergence and plasticity shape adaptive potential of the Pacific oyster海洋生态学、蛋白质翻译后修饰Nature Ecology & Evolution2018年9月": [
      15.46
    ],
    "8SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability表观遗传学、蛋白质翻译后修饰Nat Communication2016年7月": [
      14.919
    ],
    "9Global crotonylome reveals CDYL-regulated RPA1 crotonylation in homologous recombination-mediated DNA repair表观遗传学、蛋白质翻译后修饰Science Advances2020年3月": [
      14.136
    ],
    "10Dynamics and functional interplay of histone lysine butyrylation crotonylationand acetylation in rice under starvation and submergence植物学、表观遗传学、蛋白质翻译后修饰Genome Biology2018年9月": [
      13.583
    ],
    "title": [
      "影响 因子"
    ]
  },
  "187-1.xlsx": {
    "研发费用": [
      1281.96,
      3563.65,
      2223.38,
      1230.59
    ],
    "营业收入": [
      8932.54,
      22105.09,
      15348.24,
      11595.3
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年",
      "2019年"
    ]
  },
  "207-1.xlsx": {
    "哲鼎生物科技（杭州）有限公司房屋建筑物": [
      0.93,
      0.9,
      0.0,
      0.0
    ],
    "title": [
      "2022年1-6月确认的租赁收入",
      "2021年度确认的租赁 收入",
      "2020年度确认的租赁 收入",
      "2019年度确认的租赁 收入"
    ]
  },
  "207-2.xlsx": {
    "上海绿谷制药有限公司蛋白质组学技术服务": [
      0.0,
      27.51,
      96.6,
      0.0
    ],
    "青岛海洋生物医药研究院股份有限公司蛋白质组学技术服务": [
      8.6,
      0.98,
      0.0,
      0.0
    ],
    "杭州汇健科技有限公司蛋白质组学技术服务": [
      0.0,
      1.27,
      0.0,
      0.75
    ],
    "title": [
      "2022年 1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "207-3.xlsx": {
    "恺佧生物科技（上海）有限公司原材料": [
      0.0,
      0.0,
      3.9,
      0.0
    ],
    "title": [
      "2022年 1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "208-2.xlsx": {
    "1上海江村": [
      615.0,
      41.0,
      78.59375
    ],
    "2蒋旦如": [
      600.0,
      40.0,
      68.75
    ],
    "3程仲毅": [
      195.0,
      13.0,
      22.34375
    ],
    "4丁健": [
      75.0,
      5.0,
      8.59375
    ],
    "5赵雷杰": [
      15.0,
      1.0,
      1.71875
    ],
    "title": [
      "认缴发行人出资额（万元）",
      "认缴发行人出资额占注册资本比例（%）",
      "本次向杭州哲驰转让的出资额（万元）"
    ]
  },
  "209-1.xlsx": {
    "上海绿谷制药有限公司从关联方借入一名人员": [
      0.0,
      0.0,
      21.23,
      20.39
    ],
    "title": [
      "2022年 1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "209-2_210-1.xlsx": {
    "上海绿谷制药有限公司应收账款": [
      0.0,
      0.0,
      0.0,
      0.0,
      101.24,
      5.06,
      0.0,
      0.0
    ],
    "青岛海洋生物医药研究院股份有限公司应收账款": [
      5.11,
      0.26,
      0.42,
      0.02,
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "哲鼎生物科技（杭州）有限公司其他应收款": [
      0.0,
      0.0,
      0.98,
      0.05,
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "金洪元其他应收款": [
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      85.52,
      4.28
    ],
    "Yingming Zhao其他应收款": [
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.33,
      0.02
    ],
    "title": [
      "2022.6.30账面 余额",
      "2022.6.30坏账 准备",
      "2021.12.31账面 余额",
      "2021.12.31坏账 准备",
      "2020.12.31账面 余额",
      "2020.12.31坏账 准备",
      "2019.12.31账面 余额",
      "2019.12.31坏账 准备"
    ]
  },
  "21-2.xlsx": {
    "资产总额（万元）": [
      67661.97,
      67398.46,
      55622.15,
      18299.44
    ],
    "负债总额（万元）": [
      11005.84,
      11809.98,
      10237.38,
      15444.79
    ],
    "归属于母公司股东所有者权益 （万元）": [
      56656.13,
      55588.47,
      45384.77,
      2854.65
    ],
    "资产负债率（母公司）（%）": [
      15.98,
      17.17,
      18.34,
      84.0
    ],
    "营业收入（万元）": [
      8932.54,
      22105.09,
      15348.24,
      11595.3
    ],
    "净利润（万元）": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "归属于母公司股东净利润（万元）": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "扣除非经常性损益后归属于母公司股东净利润（万元）": [
      828.58,
      5277.79,
      3320.39,
      2130.23
    ],
    "加权平均净资产收益率（%）": [
      1.68,
      13.59,
      40.1,
      138.04
    ],
    "经营活动产生的现金流量净额（万元）": [
      -1432.81,
      3911.04,
      4128.29,
      4321.25
    ],
    "现金分红（万元）": [
      0.0,
      900.0,
      0.0,
      0.0
    ],
    "研发投入占营业收入的比例（%）": [
      14.35,
      16.12,
      14.49,
      10.61
    ],
    "title": [
      "2022年6月30日/2022年",
      "2021年12月31日/2021年",
      "2020年12月31日/2020年",
      "2019年12月31日/2019年"
    ]
  },
  "210-2.xlsx": {
    "青岛海洋生物医药研究院股份有限公司合同负债": [
      0.0,
      3.92,
      4.91,
      0.0
    ],
    "程仲毅其他应付款": [
      0.0,
      0.0,
      0.0,
      5.4
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "213-1_214-1.xlsx": {
    "货币资金": [
      361099986.12,
      434467421.19,
      134161194.4,
      55078936.4
    ],
    "交易性金融资产": [
      0.0,
      0.0,
      295488530.03,
      80012931.51
    ],
    "应收账款": [
      95189027.03,
      72417146.38,
      41416893.28,
      14585081.11
    ],
    "预付款项": [
      1948312.28,
      1864371.01,
      2777324.36,
      334720.59
    ],
    "其他应收款": [
      1974582.83,
      1785838.49,
      2041696.08,
      2417750.52
    ],
    "存货": [
      27429585.66,
      23120634.41,
      7134398.3,
      4253707.1
    ],
    "其他流动资产": [
      14235376.22,
      5297583.2,
      9496305.13,
      6461343.9
    ],
    "流动资产合计": [
      501876870.14,
      538952994.68,
      492516341.58,
      163144471.13
    ],
    "固定资产": [
      41421636.72,
      37392553.33,
      40139584.9,
      14811604.88
    ],
    "在建工程": [
      48064120.54,
      8576716.51,
      0.0,
      765252.83
    ],
    "使用权资产": [
      36350075.25,
      37240274.66,
      0.0,
      0.0
    ],
    "无形资产": [
      22378815.87,
      21973959.76,
      1826538.31,
      900273.33
    ],
    "长期待摊费用": [
      20628124.25,
      19434195.56,
      18322965.23,
      0.0
    ],
    "递延所得税资产": [
      3669727.87,
      2810709.81,
      1768500.1,
      3372839.94
    ],
    "其他非流动资产": [
      2230345.21,
      7603174.08,
      1647527.14,
      0.0
    ],
    "非流动资产合计": [
      174742845.71,
      135031583.71,
      63705115.68,
      19849970.98
    ],
    "资产总计": [
      676619715.85,
      673984578.39,
      556221457.26,
      182994442.11
    ],
    "短期借款": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "应付账款": [
      13736113.42,
      9297892.3,
      17820944.68,
      4522167.92
    ],
    "预收款项": [
      0.0,
      0.0,
      0.0,
      57336985.76
    ],
    "合同负债": [
      41290390.63,
      48213939.61,
      65045074.19,
      0.0
    ],
    "应付职工薪酬": [
      13209151.91,
      18458114.03,
      14146125.11,
      9856382.37
    ],
    "应交税费": [
      448607.44,
      316188.89,
      401115.58,
      1648273.11
    ],
    "其他应付款": [
      2315469.19,
      1492629.5,
      1485714.24,
      81084083.15
    ],
    "一年内到期的非流动负债": [
      4165426.09,
      3596360.01,
      0.0,
      0.0
    ],
    "流动负债合计": [
      75165158.68,
      81375124.34,
      98898973.8,
      154447892.31
    ],
    "租赁负债": [
      33307429.91,
      34509219.5,
      0.0,
      0.0
    ],
    "递延收益": [
      1585850.54,
      2215503.09,
      3474808.19,
      0.0
    ],
    "递延所得税负债": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "非流动负债合计": [
      34893280.45,
      36724722.59,
      3474808.19,
      0.0
    ],
    "负债合计": [
      110058439.13,
      118099846.93,
      102373781.99,
      154447892.31
    ],
    "股本": [
      360000000.0,
      360000000.0,
      360000000.0,
      15000000.0
    ],
    "资本公积": [
      123609958.57,
      122235118.81,
      79398840.66,
      9507352.18
    ],
    "其他综合收益": [
      -219415.36,
      -74016.84,
      -120342.9,
      -200183.39
    ],
    "盈余公积": [
      8496796.52,
      8496796.52,
      1563731.34,
      486888.33
    ],
    "未分配利润": [
      74673936.99,
      65226832.97,
      13005446.17,
      3752492.68
    ],
    "归属于母公司所有者权益合计": [
      566561276.72,
      555884731.46,
      453847675.27,
      28546549.8
    ],
    "所有者权益合计": [
      566561276.72,
      555884731.46,
      453847675.27,
      28546549.8
    ],
    "负债和所有者权益总计": [
      676619715.85,
      673984578.39,
      556221457.26,
      182994442.11
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "214-2_215-1_216-1.xlsx": {
    "一、营业总收入": [
      89325414.31,
      221050862.97,
      153482443.2,
      115953044.27
    ],
    "二、营业总成本": [
      73943545.16,
      155167854.31,
      113324770.12,
      91302312.42
    ],
    "其中：营业成本": [
      20654942.28,
      37118644.96,
      27430988.93,
      23591897.33
    ],
    "税金及附加": [
      72449.41,
      615408.21,
      270193.36,
      810015.68
    ],
    "销售费用": [
      19237353.54,
      41072379.36,
      32219354.21,
      34313275.0
    ],
    "管理费用": [
      24086943.37,
      46192044.97,
      31318872.68,
      19483144.94
    ],
    "研发费用": [
      12819627.64,
      35636501.85,
      22233792.62,
      12305948.07
    ],
    "财务费用": [
      -2927771.08,
      -5467125.04,
      -148431.68,
      798031.4
    ],
    "其中：利息费用": [
      877077.86,
      1352374.74,
      0.0,
      847158.84
    ],
    "利息收入": [
      3519041.58,
      7068569.68,
      580178.27,
      158128.25
    ],
    "加：其他收益": [
      1435967.62,
      17064437.26,
      6741390.96,
      2100329.89
    ],
    "投资收益（损失以“-”号填列）": [
      0.0,
      475766.46,
      2223313.96,
      200438.36
    ],
    "公允价值变动收益（损失以“-”号填列）": [
      0.0,
      0.0,
      475598.52,
      12931.51
    ],
    "信用减值损失（损失以“-”号填列）": [
      -4986921.2,
      -3411707.9,
      -1833943.88,
      -592952.85
    ],
    "资产减值损失（损失以“-”号填列）": [
      -1641876.08,
      -1864797.63,
      -1083983.29,
      -131916.51
    ],
    "资产处置收益（损失以“-”号填列）": [
      0.0,
      622795.96,
      75471.7,
      0.0
    ],
    "三、营业利润（亏损总额以“-”号填列）": [
      10189039.49,
      78769502.81,
      46755521.05,
      26239562.25
    ],
    "加：营业外收入": [
      34008.47,
      39000.0,
      48021.05,
      41641.37
    ],
    "减：营业外支出": [
      103764.56,
      104415.33,
      6202.71,
      150105.0
    ],
    "四、利润总额（亏损总额以“-”号填列）": [
      10119283.4,
      78704087.48,
      46797339.39,
      26131098.62
    ],
    "减：所得税费用": [
      672179.38,
      10549635.5,
      5469507.6,
      2954390.81
    ],
    "五、净利润（净亏损以“-”号填列）": [
      9447104.02,
      68154451.98,
      41327831.79,
      23176707.81
    ],
    "其中：持续经营净利润（净亏损以“-”号填列": [
      9447104.02,
      68154451.98,
      41327831.79,
      23176707.81
    ],
    "终止经营净利润": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "其中：归属于母公司股东的净利润（净亏损以“-”号填列）": [
      9447104.02,
      68154451.98,
      41327831.79,
      23176707.81
    ],
    "少数股东损益": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "六、其他综合收益的税后净额": [
      -145398.52,
      46326.06,
      79840.49,
      11720.08
    ],
    "七、综合收益总额": [
      9301705.5,
      68200778.04,
      41407672.28,
      23188427.89
    ],
    "归属于母公司股东的综合收益总额": [
      9301705.5,
      68200778.04,
      41407672.28,
      23188427.89
    ],
    "归属于少数股东的综合收益总额": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "216-2_217-1.xlsx": {
    "销售商品、提供劳务收到的现金": [
      58908222.48,
      185121246.73,
      141513791.57,
      135939710.05
    ],
    "收到的税费返还": [
      1274976.54,
      238991.67,
      0.0,
      0.0
    ],
    "收到其他与经营活动有关的现金": [
      4978434.98,
      21791076.37,
      11968667.96,
      2143617.91
    ],
    "经营活动现金流入小计": [
      65161634.0,
      207151314.77,
      153482459.53,
      138083327.96
    ],
    "购买商品、接受劳务支付的现金": [
      12878525.17,
      33749808.86,
      20868182.93,
      10994376.64
    ],
    "支付给职工以及为职工支付的现金": [
      53814221.29,
      88296891.19,
      60183222.43,
      56717050.01
    ],
    "支付的各项税费": [
      2674934.0,
      16304006.56,
      9140871.04,
      10353504.33
    ],
    "支付其他与经营活动有关的现金": [
      10122067.03,
      29690223.8,
      22007331.99,
      16805915.83
    ],
    "经营活动现金流出小计": [
      79489747.49,
      168040930.41,
      112199608.39,
      94870846.81
    ],
    "经营活动产生的现金流量净额": [
      -14328113.49,
      39110384.36,
      41282851.14,
      43212481.15
    ],
    "收回投资收到的现金": [
      0.0,
      295000000.0,
      560000000.0,
      80000000.0
    ],
    "取得投资收益收到的现金": [
      0.0,
      964296.49,
      2223313.96,
      200438.36
    ],
    "处置固定资产、无形资产和其他长期资产收回的现金净额": [
      610.0,
      800440.04,
      75471.7,
      0.0
    ],
    "收到其他与投资活动有关的现金": [
      8670000.0,
      0.0,
      3000000.0,
      0.0
    ],
    "投资活动现金流入小计": [
      8670610.0,
      296764736.53,
      565298785.66,
      80200438.36
    ],
    "购置固定资产、无形资产和其他长期资产支付的现金": [
      49221989.14,
      54886580.35,
      49476087.97,
      11976874.02
    ],
    "投资支付的现金": [
      0.0,
      0.0,
      775000000.0,
      160000000.0
    ],
    "支付其他与投资活动有关的现金": [
      0.0,
      7600000.0,
      1500000.0,
      3000000.0
    ],
    "投资活动现金流出小计": [
      49221989.14,
      62486580.35,
      825976087.97,
      174976874.02
    ],
    "投资活动产生的现金流量净额": [
      -40551379.14,
      234278156.18,
      -260677302.31,
      -94776435.66
    ],
    "吸收投资收到的现金": [
      0.0,
      0.0,
      300000000.0,
      80000000.0
    ],
    "取得借款收到的现金": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "收到其他与筹资活动有关的现金": [
      0.0,
      35197716.79,
      0.0,
      0.0
    ],
    "筹资活动现金流入小计": [
      0.0,
      35197716.79,
      300000000.0,
      80000000.0
    ],
    "偿还债务支付的现金": [
      0.0,
      0.0,
      0.0,
      5000000.0
    ],
    "分配股利、利润或偿付利息支付的现金": [
      0.0,
      9000000.0,
      0.0,
      361050.0
    ],
    "支付其他与筹资活动有关的现金": [
      9994499.18,
      6793168.26,
      0.0,
      8500000.0
    ],
    "筹资活动现金流出小计": [
      9994499.18,
      15793168.26,
      0.0,
      13861050.0
    ],
    "筹资活动产生的现金流量净额": [
      -9994499.18,
      19404548.53,
      300000000.0,
      66138950.0
    ],
    "四、汇率变动对现金及现金等价物的影响": [
      171756.74,
      -70742.28,
      -171770.83,
      42025.18
    ],
    "五、现金及现金等价物净增加额": [
      -64702235.07,
      292722346.79,
      80433778.0,
      14617020.67
    ],
    "加：期初现金及现金等价物余额": [
      425235061.19,
      132512714.4,
      52078936.4,
      37461915.73
    ],
    "六、期末现金及现金等价物余额": [
      360532826.12,
      425235061.19,
      132512714.4,
      52078936.4
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "229-3.xlsx": {
    "1年以内（含，下同）": [
      5.0
    ],
    "1-2年": [
      20.0
    ],
    "2-3年": [
      40.0
    ],
    "3年以上": [
      100.0
    ],
    "title": [
      "应收账款预期信用损失率（%）"
    ]
  },
  "234-1.xlsx": {
    "运输工具年限平均法": [
      4.0,
      3.0,
      24.25
    ],
    "title": [
      "折旧年限（年）",
      "残值率（%）",
      "年折旧率（%）"
    ]
  },
  "234-2.xlsx": {
    "土地使用权": [
      50.0
    ],
    "title": [
      "摊销年限（年）"
    ]
  },
  "244-1.xlsx": {
    "预收款项": [
      5733.7,
      -5733.7,
      0.0
    ],
    "合同负债": [
      0.0,
      5733.7,
      5733.7
    ],
    "title": [
      "资产负债表2019年12月31日",
      "资产负债表新收入准则调整影响",
      "资产负债表2020年1月1日"
    ]
  },
  "245-1.xlsx": {
    "使用权资产": [
      0.0,
      4070.55,
      4070.55
    ],
    "一年内到期的非流动负债": [
      0.0,
      344.49,
      344.49
    ],
    "租赁负债": [
      0.0,
      3726.07,
      3726.07
    ],
    "title": [
      "资产负债表2020年12月31日",
      "资产负债表新租赁准则调整影响",
      "资产负债表2021年1月1日"
    ]
  },
  "247-1.xlsx": {
    "所得税优惠金额": [
      102.08,
      773.82,
      358.5,
      179.91
    ],
    "利润总额": [
      1011.93,
      7870.41,
      4679.73,
      2613.11
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "247-2.xlsx": {
    "母公司利润总额": [
      1096.62,
      7966.17,
      4714.36,
      2486.58
    ],
    "纳税调整": [
      -75.82,
      -239.1,
      -1129.35,
      -687.44
    ],
    "应纳税所得额": [
      1020.8,
      7727.07,
      3585.0,
      1799.13
    ],
    "税收优惠金额": [
      102.08,
      772.71,
      358.5,
      179.91
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "247-3_248-1.xlsx": {
    "非流动资产处置损益，包括已计提资产减值准备的冲": [
      -0.21,
      62.02,
      6.93,
      -0.01
    ],
    "计入当期损益的政府补助（与公司正常经营业务密切相关，符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外）": [
      103.4,
      1556.39,
      651.71,
      184.16
    ],
    "除同公司正常经营业务相关的有效套期保值业务外，持有以公允价值计量且其变动计入当期损益的金融资产、金融负债产生的公允价值变动收益，以及处置以公允价值计量且其变动计入当期损益的金融资产、金融负债和可供出售金融资产取得的投资收益": [
      0.0,
      47.58,
      269.89,
      21.34
    ],
    "除上述各项之外的其他营业外收入和支出": [
      -6.76,
      -6.28,
      4.8,
      -10.84
    ],
    "其他符合非经常性损益定义的损益项目": [
      40.19,
      150.05,
      22.43,
      25.87
    ],
    "非经常性损益总额": [
      136.62,
      1809.76,
      955.76,
      220.52
    ],
    "减：所得税费用（所得税费用减少以“-” 表示）": [
      20.49,
      272.11,
      143.36,
      33.08
    ],
    "少数股东损益": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "归属于母公司股东的非经常性损益净额": [
      116.13,
      1537.65,
      812.4,
      187.45
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "248-2_249-1.xlsx": {
    "流动比率（倍）": [
      6.68,
      6.62,
      4.98,
      1.06
    ],
    "速动比率（倍）": [
      6.31,
      6.34,
      4.91,
      1.03
    ],
    "应收账款周转率（次/年）": [
      1.07,
      3.88,
      5.48,
      10.85
    ],
    "存货周转率（次/年）": [
      0.82,
      2.45,
      4.82,
      4.73
    ],
    "息税折旧摊销前利润（万元）": [
      2238.44,
      9875.12,
      5378.21,
      3171.57
    ],
    "归属于公司普通股东的每股净资产（元）": [
      1.57,
      1.54,
      1.26,
      1.9
    ],
    "每股经营活动产生的现金流量净额（元）": [
      -0.04,
      0.11,
      0.11,
      2.88
    ],
    "每股净现金流量（元）": [
      -0.18,
      0.81,
      0.22,
      0.97
    ],
    "归属于母公司股东的净利润（万元）": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "扣除非经常性损益后归属于母公司股东的净利润（万元）": [
      828.58,
      5277.79,
      3320.39,
      2130.23
    ],
    "title": [
      "2022年1-6月/2022年6月30日",
      "2021年度/2021年12月31日",
      "2020年度/2020年12月31日",
      "2019年度/2019年12月31日"
    ]
  },
  "249-2_250-1.xlsx": {
    "归属于公司普通股股东的净利润": [
      40.1,
      0.11,
      0.11
    ],
    "扣除非经常性损益后归属于公司普通股股东的净利润": [
      32.21,
      0.09,
      0.09
    ],
    "title": [
      "加权平均 净资产收益率（%）",
      "每股收益（元）基本",
      "每股收益（元）稀释"
    ]
  },
  "251-1.xlsx": {
    "主营业务收入": [
      8931.62,
      99.99,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "其他业务收入": [
      0.93,
      0.01,
      0.9,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "营业收入": [
      8932.54,
      100.0,
      22105.09,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例（%）",
      "2021年度金额",
      "2021年度比例（%）",
      "2020年度金额",
      "2020年度比例（%）",
      "2019年度金额",
      "2019年度比例（%）"
    ]
  },
  "252-1.xlsx": {
    "蛋白质组学技术服务": [
      6754.56,
      75.63,
      17137.86,
      77.53,
      14308.07,
      93.22,
      11028.78,
      95.11
    ],
    "抗体试剂产品": [
      2177.06,
      24.37,
      4966.32,
      22.47,
      1040.18,
      6.78,
      566.52,
      4.89
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例（%）",
      "2021年度金额",
      "2021年度比例（%）",
      "2020年度金额",
      "2020年度比例（%）",
      "2019年度金额",
      "2019年度比例（%）"
    ]
  },
  "252-2.xlsx": {
    "蛋白质组分析": [
      3683.44,
      41.24,
      8952.01,
      40.5,
      6459.71,
      42.09,
      5637.92,
      48.62
    ],
    "蛋白质修饰组分析": [
      3071.12,
      34.38,
      8185.85,
      37.03,
      7848.36,
      51.14,
      5390.87,
      46.49
    ],
    "合计": [
      6754.56,
      75.63,
      17137.86,
      77.53,
      14308.07,
      93.22,
      11028.78,
      95.11
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例（%）",
      "2021年度金额",
      "2021年度比例（%）",
      "2020年度金额",
      "2020年度比例（%）",
      "2019年度金额",
      "2019年度比例（%）"
    ]
  },
  "254-1.xlsx": {
    "蛋白质修饰组分析销量GB": [
      3396.7,
      7387.55,
      4975.43,
      2791.58
    ],
    "蛋白质修饰组分析销售单价元/GB": [
      8828.87,
      10731.23,
      15415.6,
      18571.31
    ],
    "蛋白质组分析销量GB": [
      15252.27,
      35587.23,
      21148.89,
      14801.47
    ],
    "蛋白质组分析销售单价元/GB": [
      2005.63,
      2183.0,
      2522.37,
      3206.35
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年",
      "2019年"
    ]
  },
  "255-1.xlsx": {
    "抗体试剂产品收入万元": [
      2177.06,
      4966.32,
      1040.18,
      566.52
    ],
    "抗体试剂产品销量μl": [
      1083830.0,
      2324245.0,
      433770.0,
      218960.0
    ],
    "抗体试剂产品销售单价元/μl": [
      20.09,
      21.37,
      23.98,
      25.87
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年",
      "2019年"
    ]
  },
  "255-2_256-1.xlsx": {
    "境内": [
      8764.51,
      98.13,
      21816.9,
      98.7,
      15059.99,
      98.12,
      11416.8,
      98.46
    ],
    "东北": [
      548.41,
      6.14,
      1780.66,
      8.06,
      1046.28,
      6.82,
      848.77,
      7.32
    ],
    "华北": [
      2854.3,
      31.96,
      5899.03,
      26.69,
      3199.23,
      20.84,
      2800.5,
      24.15
    ],
    "华东": [
      2252.32,
      25.22,
      5577.54,
      25.23,
      4016.2,
      26.17,
      2909.64,
      25.09
    ],
    "华南": [
      1227.39,
      13.74,
      2973.96,
      13.45,
      2123.33,
      13.83,
      1175.26,
      10.14
    ],
    "华中": [
      617.33,
      6.91,
      1625.95,
      7.36,
      2143.49,
      13.97,
      1370.8,
      11.82
    ],
    "西北": [
      324.05,
      3.63,
      1391.3,
      6.29,
      721.05,
      4.7,
      775.54,
      6.69
    ],
    "西南": [
      940.71,
      10.53,
      2568.46,
      11.62,
      1810.4,
      11.8,
      1536.29,
      13.25
    ],
    "境外": [
      167.1,
      1.87,
      287.28,
      1.3,
      288.25,
      1.88,
      178.51,
      1.54
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例 （%）",
      "2021年度金额",
      "2021年度比例 （%）",
      "2020年度金额",
      "2020年度比例 （%）",
      "2019年度金额",
      "2019年度比例 （%）"
    ]
  },
  "256-2.xlsx": {
    "第一季度": [
      3718.34,
      41.63,
      3223.33,
      14.58,
      1729.24,
      11.27,
      1761.88,
      15.19
    ],
    "第二季度": [
      5213.27,
      58.37,
      4955.47,
      22.42,
      3380.8,
      22.03,
      2497.18,
      21.54
    ],
    "第三季度不适用不适用": [
      5663.82,
      25.62,
      4065.04,
      26.49,
      2621.79,
      22.61
    ],
    "第四季度不适用不适用": [
      8261.56,
      37.38,
      6173.16,
      40.22,
      4714.45,
      40.66
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例 （%）",
      "2021年度金额",
      "2021年度比例 （%）",
      "2020年度金额",
      "2020年度比例 （%）",
      "2019年度金额",
      "2019年度比例 （%）"
    ]
  },
  "257-1.xlsx": {
    "主营业务成本": [
      2065.49,
      100.0,
      3711.86,
      100.0,
      2743.1,
      100.0,
      2359.19,
      100.0
    ],
    "合计": [
      2065.49,
      100.0,
      3711.86,
      100.0,
      2743.1,
      100.0,
      2359.19,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月占比 （%）",
      "2021年度金额",
      "2021年度占比 （%）",
      "2020年度金额",
      "2020年度占比 （%）",
      "2019年度金额",
      "2019年度占比 （%）"
    ]
  },
  "257-2_258-1.xlsx": {
    "蛋白质组学技术服务": [
      1960.2,
      94.9,
      3494.31,
      94.14,
      2690.74,
      98.09,
      2319.72,
      98.33
    ],
    "抗体试剂产品": [
      105.29,
      5.1,
      217.56,
      5.86,
      52.36,
      1.91,
      39.47,
      1.67
    ],
    "合计": [
      2065.49,
      100.0,
      3711.86,
      100.0,
      2743.1,
      100.0,
      2359.19,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月占比 （%）",
      "2021年度金额",
      "2021年度占比 （%）",
      "2020年度金额",
      "2020年度占比 （%）",
      "2019年度金额",
      "2019年度占比 （%）"
    ]
  },
  "258-2.xlsx": {
    "直接材料": [
      280.44,
      13.58,
      571.2,
      15.39,
      404.19,
      14.73,
      342.04,
      14.5
    ],
    "直接人工": [
      852.0,
      41.25,
      1547.38,
      41.69,
      1228.0,
      44.77,
      1222.66,
      51.83
    ],
    "制造费用": [
      933.05,
      45.17,
      1593.28,
      42.92,
      1110.91,
      40.5,
      794.5,
      33.68
    ],
    "合计": [
      2065.49,
      100.0,
      3711.86,
      100.0,
      2743.1,
      100.0,
      2359.19,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月占比 （%）",
      "2021年度金额",
      "2021年度占比 （%）",
      "2020年度金额",
      "2020年度占比 （%）",
      "2019年度金额",
      "2019年度占比 （%）"
    ]
  },
  "260-1.xlsx": {
    "主营业务": [
      6866.12,
      99.99,
      18392.32,
      100.0,
      12605.15,
      100.0,
      9236.11,
      100.0
    ],
    "其他业务": [
      0.93,
      0.01,
      0.9,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "合计": [
      6867.05,
      100.0,
      18393.22,
      100.0,
      12605.15,
      100.0,
      9236.11,
      100.0
    ],
    "title": [
      "2022年1-6月毛利",
      "2022年1-6月占比 （%）",
      "2021年度毛利",
      "2021年度占比 （%）",
      "2020年度毛利",
      "2020年度占比 （%）",
      "2019年度毛利",
      "2019年度占比 （%）"
    ]
  },
  "260-2.xlsx": {
    "1蛋白质组学技术服务": [
      70.98,
      75.63,
      79.61,
      77.53,
      81.19,
      93.22,
      78.97,
      95.11
    ],
    "2抗体试剂产品": [
      95.16,
      24.37,
      95.62,
      22.47,
      94.97,
      6.78,
      93.03,
      4.89
    ],
    "-合计": [
      76.87,
      100.0,
      83.21,
      100.0,
      82.13,
      100.0,
      79.65,
      100.0
    ],
    "title": [
      "2022年1-6月毛利率（%）",
      "2022年1-6月占收入比例（%）",
      "2021年度毛利率（%）",
      "2021年度占收入比例（%）",
      "2020年度毛利率（%）",
      "2020年度占收入比例（%）",
      "2019年度毛利率（%）",
      "2019年度占收入比例（%）"
    ]
  },
  "261-1.xlsx": {
    "1蛋白质组学技术服务": [
      70.98,
      75.63,
      79.61,
      77.53,
      81.19,
      93.22,
      78.97,
      95.11
    ],
    "1.1蛋白质组分析": [
      64.32,
      41.24,
      75.33,
      40.5,
      76.2,
      42.09,
      76.36,
      48.62
    ],
    "1.2蛋白质修饰组分析": [
      78.96,
      34.38,
      84.29,
      37.03,
      85.3,
      51.14,
      81.69,
      46.49
    ],
    "2抗体试剂产品": [
      95.16,
      24.37,
      95.62,
      22.47,
      94.97,
      6.78,
      93.03,
      4.89
    ],
    "-合计": [
      76.87,
      100.0,
      83.21,
      100.0,
      82.13,
      100.0,
      79.65,
      100.0
    ],
    "title": [
      "2022年1-6月毛利率（%）",
      "2022年1-6月占收入比例（%）",
      "2021年度毛利率（%）",
      "2021年度占收入比例（%）",
      "2020年度毛利率（%）",
      "2020年度占收入比例（%）",
      "2019年度毛利率（%）",
      "2019年度占收入比例（%）"
    ]
  },
  "264-1.xlsx": {
    "诺禾致源": [
      42.21,
      42.89,
      35.12,
      39.15
    ],
    "华大基因": [
      54.08,
      58.09,
      60.07,
      53.56
    ],
    "优宁维": [
      22.6,
      23.19,
      22.77,
      22.27
    ],
    "菲鹏生物": [
      -1.0,
      88.5,
      93.95,
      92.7
    ],
    "可比公司均值": [
      39.63,
      53.17,
      52.98,
      51.92
    ],
    "景杰生物": [
      76.87,
      83.21,
      82.13,
      79.65
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年"
    ]
  },
  "264-2_265-1.xlsx": {
    "销售费用金额": [
      1923.74,
      4107.24,
      3221.94,
      3431.33
    ],
    "管理费用金额": [
      2408.69,
      4619.2,
      3131.89,
      1948.31
    ],
    "研发费用金额": [
      1281.96,
      3563.65,
      2223.38,
      1230.59
    ],
    "财务费用金额": [
      -292.78,
      -546.71,
      -14.84,
      79.8
    ],
    "合计金额": [
      5321.62,
      11743.38,
      8562.36,
      6690.04
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "265-2_266-1.xlsx": {
    "职工薪酬": [
      1550.35,
      80.59,
      3537.72,
      86.13,
      2717.21,
      84.33,
      2806.65,
      81.8
    ],
    "货样赠品": [
      110.81,
      5.76,
      5.51,
      0.13,
      0.61,
      0.02,
      0.0,
      0.0
    ],
    "办公、差旅费": [
      64.36,
      3.35,
      203.32,
      4.95,
      188.68,
      5.86,
      242.89,
      7.08
    ],
    "业务宣传费": [
      52.62,
      2.74,
      116.98,
      2.85,
      105.58,
      3.28,
      143.19,
      4.17
    ],
    "租赁费": [
      33.54,
      1.74,
      86.79,
      2.11,
      114.97,
      3.57,
      114.08,
      3.32
    ],
    "股份支付": [
      20.4,
      1.06,
      59.48,
      1.45,
      52.36,
      1.63,
      0.0,
      0.0
    ],
    "折旧与摊销": [
      50.74,
      2.64,
      39.03,
      0.95,
      3.87,
      0.12,
      2.17,
      0.06
    ],
    "外部服务费": [
      20.72,
      1.08,
      27.91,
      0.68,
      16.15,
      0.5,
      12.1,
      0.35
    ],
    "运杂费": [
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      91.05,
      2.65
    ],
    "其他": [
      20.2,
      1.05,
      30.5,
      0.74,
      22.51,
      0.7,
      19.19,
      0.56
    ],
    "合计": [
      1923.74,
      100.0,
      4107.24,
      100.0,
      3221.94,
      100.0,
      3431.33,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月占比 （%）",
      "2021年度金额",
      "2021年度占比 （%）",
      "2020年度金额",
      "2020年度占比 （%）",
      "2019年金额",
      "2019年占比 （%）"
    ]
  },
  "268-1.xlsx": {
    "诺禾致源": [
      18.61,
      14.7,
      15.81,
      14.97
    ],
    "华大基因": [
      19.49,
      18.3,
      12.84,
      22.09
    ],
    "优宁维": [
      9.22,
      6.94,
      7.94,
      8.42
    ],
    "菲鹏生物": [
      -1.0,
      5.58,
      5.43,
      12.82
    ],
    "可比公司平均值": [
      15.77,
      11.38,
      10.51,
      14.57
    ],
    "景杰生物": [
      21.54,
      18.58,
      20.99,
      29.59
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "270-1.xlsx": {
    "职工薪酬（万元）": [
      1182.83,
      2029.07,
      1295.96,
      975.61
    ],
    "全年平均人数（人）": [
      55.17,
      48.25,
      33.08,
      29.33
    ],
    "人均薪酬（万元）": [
      21.44,
      42.05,
      39.18,
      33.26
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "271-1.xlsx": {
    "中介服务费": [
      52.23,
      203.55,
      180.44,
      201.79
    ],
    "顾问费": [
      37.58,
      42.63,
      29.45,
      44.42
    ],
    "保安、保洁服务费": [
      17.75,
      28.96,
      9.04,
      0.29
    ],
    "信息系统服务费": [
      21.27,
      26.97,
      26.23,
      60.02
    ],
    "其他": [
      11.76,
      44.76,
      35.86,
      24.42
    ],
    "合计": [
      140.6,
      346.88,
      281.02,
      330.94
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "271-2.xlsx": {
    "诺禾致源": [
      -1.0,
      37.14,
      31.61,
      26.29
    ],
    "华大基因": [
      -1.0,
      30.66,
      68.51,
      19.86
    ],
    "优宁维": [
      -1.0,
      24.65,
      19.71,
      18.75
    ],
    "菲鹏生物": [
      -1.0,
      35.15,
      32.23,
      28.75
    ],
    "可比公司均值": [
      -1.0,
      31.9,
      38.02,
      23.41
    ],
    "景杰生物": [
      21.44,
      42.05,
      39.18,
      33.26
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "272-1.xlsx": {
    "诺禾致源": [
      10.59,
      8.0,
      8.48,
      8.17
    ],
    "华大基因": [
      5.55,
      5.72,
      6.47,
      7.05
    ],
    "优宁维": [
      2.93,
      2.85,
      2.8,
      2.95
    ],
    "菲鹏生物": [
      -1.0,
      4.75,
      5.79,
      18.42
    ],
    "可比上市公司平均值": [
      6.36,
      5.33,
      5.89,
      9.15
    ],
    "景杰生物": [
      26.97,
      20.9,
      20.41,
      16.8
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "274-1.xlsx": {
    "引物合成、DNA合成及DNA测序": [
      145.97,
      231.87,
      60.64,
      0.84
    ],
    "多肽合成": [
      44.75,
      97.22,
      158.75,
      30.36
    ],
    "实验动物费": [
      75.77,
      157.49,
      170.28,
      79.32
    ],
    "质谱仪租赁费": [
      82.6,
      370.51,
      72.27,
      0.0
    ],
    "其他": [
      0.75,
      0.06,
      11.23,
      2.58
    ],
    "合计": [
      349.84,
      857.16,
      473.18,
      113.1
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "276-2_277-1.xlsx": {
    "诺禾致源": [
      5.81,
      7.78,
      7.54,
      8.19
    ],
    "华大基因": [
      8.22,
      7.2,
      7.38,
      11.33
    ],
    "优宁维": [
      2.17,
      1.51,
      1.03,
      1.1
    ],
    "菲鹏生物": [
      -1.0,
      7.95,
      10.51,
      35.92
    ],
    "可比公司均值": [
      5.4,
      6.11,
      6.62,
      14.14
    ],
    "景杰生物": [
      14.35,
      16.12,
      14.49,
      10.61
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "277-2.xlsx": {
    "利息收入": [
      -351.9,
      -706.86,
      -58.02,
      -15.81
    ],
    "利息支出": [
      87.71,
      135.24,
      0.0,
      84.72
    ],
    "银行手续费": [
      4.0,
      6.11,
      7.21,
      4.46
    ],
    "汇兑损益": [
      -32.58,
      18.79,
      35.97,
      6.44
    ],
    "合计": [
      -292.78,
      -546.71,
      -14.84,
      79.8
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "278-1.xlsx": {
    "与资产相关的政府补助": [
      62.97,
      125.93,
      76.72,
      0.0
    ],
    "与收益相关的政府补助": [
      40.44,
      1430.46,
      574.99,
      184.16
    ],
    "增值税进项税加计抵减": [
      27.07,
      145.71,
      12.89,
      25.83
    ],
    "代扣代缴个税手续费返还": [
      13.12,
      4.34,
      9.54,
      0.04
    ],
    "合计": [
      143.6,
      1706.44,
      674.14,
      210.03
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "28-2.xlsx": {
    "邮编：": [
      518038.0
    ],
    "title": [
      "广东省深圳市福田区深南大道2012号深圳证券交易所广场22-28楼"
    ]
  },
  "280-1.xlsx": {
    "营业外收入": [
      3.4,
      3.9,
      4.8,
      4.16
    ],
    "违约金收入": [
      3.3,
      3.9,
      4.8,
      1.5
    ],
    "其他": [
      0.17,
      0.0,
      0.0,
      0.0
    ],
    "营业外支出": [
      10.38,
      10.44,
      0.62,
      15.01
    ],
    "对外捐赠": [
      10.0,
      5.0,
      0.0,
      15.0
    ],
    "税收滞纳金": [
      0.0,
      4.28,
      0.0,
      0.0
    ],
    "赔款支出": [
      0.0,
      0.9,
      0.0,
      0.0
    ],
    "固定资产报废损失": [
      0.21,
      0.26,
      0.62,
      0.01
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "280-2.xlsx": {
    "当期所得税费用": [
      153.12,
      1159.18,
      386.52,
      0.0
    ],
    "递延所得税费用": [
      -85.9,
      -104.22,
      160.43,
      295.44
    ],
    "所得税费用合计": [
      67.22,
      1054.96,
      546.95,
      295.44
    ],
    "所得税费用/利润总额（%）": [
      6.64,
      13.4,
      11.69,
      11.31
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "281-1.xlsx": {
    "期初未交": [
      -48.31,
      -92.15,
      120.78,
      73.1
    ],
    "本期应交": [
      -232.18,
      504.51,
      45.78,
      633.53
    ],
    "本期已交": [
      -127.5,
      460.67,
      258.72,
      585.85
    ],
    "期末未交": [
      -152.99,
      -48.31,
      -92.15,
      120.78
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "282-1.xlsx": {
    "期初未交": [
      -232.32,
      -839.23,
      -633.86,
      -272.38
    ],
    "本期应交": [
      153.12,
      1687.15,
      386.52,
      0.0
    ],
    "本期已交": [
      265.14,
      1080.24,
      591.88,
      361.48
    ],
    "期末未交": [
      -344.35,
      -232.32,
      -839.23,
      -633.86
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "282-2.xlsx": {
    "流动资产": [
      50187.69,
      74.17,
      53895.3,
      79.97,
      49251.63,
      88.55,
      16314.45,
      89.15
    ],
    "非流动资产": [
      17474.28,
      25.83,
      13503.16,
      20.03,
      6370.51,
      11.45,
      1985.0,
      10.85
    ],
    "合计": [
      67661.97,
      100.0,
      67398.46,
      100.0,
      55622.15,
      100.0,
      18299.44,
      100.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30占比（%）",
      "2021.12.31金额",
      "2021.12.31占比（%）",
      "2020.12.31金额",
      "2020.12.31占比（%）",
      "2019.12.31金额",
      "2019.12.31占比（%）"
    ]
  },
  "283-1.xlsx": {
    "货币资金": [
      36110.0,
      71.95,
      43446.74,
      80.61,
      13416.12,
      27.24,
      5507.89,
      33.76
    ],
    "交易性金融资产": [
      0.0,
      0.0,
      0.0,
      0.0,
      29548.85,
      60.0,
      8001.29,
      49.04
    ],
    "应收账款": [
      9518.9,
      18.97,
      7241.71,
      13.44,
      4141.69,
      8.41,
      1458.51,
      8.94
    ],
    "预付账款": [
      194.83,
      0.39,
      186.44,
      0.35,
      277.73,
      0.56,
      33.47,
      0.21
    ],
    "其他应收款": [
      197.46,
      0.39,
      178.58,
      0.33,
      204.17,
      0.41,
      241.78,
      1.48
    ],
    "存货": [
      2742.96,
      5.47,
      2312.06,
      4.29,
      713.44,
      1.45,
      425.37,
      2.61
    ],
    "其他流动资产": [
      1423.54,
      2.84,
      529.76,
      0.98,
      949.63,
      1.93,
      646.13,
      3.96
    ],
    "合计": [
      50187.69,
      100.0,
      53895.3,
      100.0,
      49251.63,
      100.0,
      16314.45,
      100.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30占比（%）",
      "2021.12.31金额",
      "2021.12.31占比（%）",
      "2020.12.31金额",
      "2020.12.31占比（%）",
      "2019.12.31金额",
      "2019.12.31占比（%）"
    ]
  },
  "283-2.xlsx": {
    "库存现金": [
      2.81,
      2.81,
      2.81,
      2.01
    ],
    "银行存款": [
      36050.47,
      42520.7,
      13248.46,
      5205.88
    ],
    "其他货币资金": [
      56.72,
      923.24,
      164.85,
      300.0
    ],
    "合计": [
      36110.0,
      43446.74,
      13416.12,
      5507.89
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "284-1.xlsx": {
    "账面余额": [
      10675.65,
      7900.3,
      4459.22,
      1591.6
    ],
    "坏账准备": [
      1156.74,
      658.58,
      317.53,
      133.09
    ],
    "账面价值": [
      9518.9,
      7241.71,
      4141.69,
      1458.51
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "287-2_288-1.xlsx": {
    "1年以内": [
      1420.06,
      89.22,
      71.0,
      5.0,
      1349.06
    ],
    "1-2年": [
      123.16,
      7.74,
      24.63,
      20.0,
      98.53
    ],
    "2-3年": [
      18.2,
      1.14,
      7.28,
      40.0,
      10.92
    ],
    "3年以上": [
      30.18,
      1.9,
      30.18,
      100.0,
      0.0
    ],
    "合计": [
      1591.6,
      100.0,
      133.09,
      8.36,
      1458.51
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30比例（%）",
      "2022.6.30坏账准备",
      "2022.6.30计提比例（%）",
      "2022.6.30净额"
    ]
  },
  "288-2_289-1.xlsx": {
    "菲鹏生物": [
      5.0,
      10.0,
      20.0,
      30.0,
      50.0,
      100.0
    ],
    "title": [
      "应收账款计提比例1年以内",
      "应收账款计提比例1-2年",
      "应收账款计提比例2-3年",
      "应收账款计提比例3-4年",
      "应收账款计提比例4-5年",
      "应收账款计提比例5年以上"
    ]
  },
  "289-2.xlsx": {
    "1年以内": [
      185.08,
      94.99,
      178.33,
      95.65,
      277.38,
      99.87,
      31.18,
      93.14
    ],
    "1-2年": [
      9.23,
      4.74,
      8.11,
      4.35,
      0.33,
      0.12,
      2.3,
      6.86
    ],
    "2-3年": [
      0.52,
      0.27,
      0.0,
      0.0,
      0.03,
      0.01,
      0.0,
      0.0
    ],
    "合计": [
      194.83,
      100.0,
      186.44,
      100.0,
      277.73,
      100.0,
      33.47,
      100.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30比例（%）",
      "2021.12.31金额",
      "2021.12.31比例（%）",
      "2020.12.31金额",
      "2020.12.31比例（%）",
      "2019.12.31金额",
      "2019.12.31比例（%）"
    ]
  },
  "292-3_293-1.xlsx": {
    "原材料": [
      141.53,
      7.89,
      133.65
    ],
    "库存商品": [
      76.88,
      16.63,
      60.25
    ],
    "在产品": [
      64.94,
      16.01,
      48.93
    ],
    "合同履约成本": [
      0.0,
      0.0,
      0.0
    ],
    "未完成劳务": [
      182.54,
      0.0,
      182.54
    ],
    "合计": [
      465.9,
      40.53,
      425.37
    ],
    "title": [
      "2022年6月30日账面余额",
      "2022年6月30日跌价准备",
      "2022年6月30日账面价值"
    ]
  },
  "294-1.xlsx": {
    "抗体试剂产品原材料": [
      928.55,
      989.24,
      367.75,
      28.19
    ],
    "库存商品": [
      1281.23,
      823.27,
      180.31,
      76.88
    ],
    "在产品": [
      558.78,
      434.4,
      152.21,
      64.94
    ],
    "抗体试剂产品存货": [
      2768.56,
      2246.91,
      700.27,
      170.01
    ],
    "存货账面余额": [
      3161.64,
      2603.38,
      840.73,
      465.9
    ],
    "title": [
      "2022.06.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "295-1.xlsx": {
    "预缴所得税": [
      344.35,
      232.34,
      839.23,
      633.86
    ],
    "上市中介服务费": [
      880.54,
      192.8,
      0.0,
      0.0
    ],
    "待摊费用": [
      43.97,
      56.31,
      18.25,
      12.27
    ],
    "增值税留抵税额": [
      154.68,
      48.31,
      92.15,
      0.0
    ],
    "合计": [
      1423.54,
      529.76,
      949.63,
      646.13
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "295-2_296-1.xlsx": {
    "固定资产": [
      4142.16,
      23.7,
      3739.26,
      27.69,
      4013.96,
      63.01,
      1481.16,
      74.62
    ],
    "在建工程": [
      4806.41,
      27.51,
      857.67,
      6.35,
      0.0,
      0.0,
      76.53,
      3.86
    ],
    "使用权资产": [
      3635.01,
      20.8,
      3724.03,
      27.58,
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "无形资产": [
      2237.88,
      12.81,
      2197.4,
      16.27,
      182.65,
      2.87,
      90.03,
      4.54
    ],
    "长期待摊费用": [
      2062.81,
      11.8,
      1943.42,
      14.39,
      1832.3,
      28.76,
      0.0,
      0.0
    ],
    "递延所得税资产": [
      366.97,
      2.1,
      281.07,
      2.08,
      176.85,
      2.78,
      337.28,
      16.99
    ],
    "其他非流动资产": [
      223.03,
      1.28,
      760.32,
      5.63,
      164.75,
      2.59,
      0.0,
      0.0
    ],
    "合计": [
      17474.28,
      100.0,
      13503.16,
      100.0,
      6370.51,
      100.0,
      1985.0,
      100.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30占比（%）",
      "2021.12.31金额",
      "2021.12.31占比（%）",
      "2020.12.31金额",
      "2020.12.31占比（%）",
      "2019.12.31金额",
      "2019.12.31占比（%）"
    ]
  },
  "296-2.xlsx": {
    "通用设备": [
      547.22,
      13.21,
      597.3,
      15.97,
      651.86,
      16.24,
      73.24,
      4.94
    ],
    "专用设备": [
      3594.37,
      86.78,
      3141.39,
      84.01,
      3361.53,
      83.75,
      1407.35,
      95.02
    ],
    "运输工具": [
      0.57,
      0.01,
      0.57,
      0.02,
      0.57,
      0.01,
      0.57,
      0.04
    ],
    "账面原值合计": [
      8105.85,
      100.0,
      7014.69,
      100.0,
      6412.23,
      100.0,
      3272.29,
      100.0
    ],
    "累计折旧合计": [
      3963.69,
      100.0,
      3275.44,
      100.0,
      2398.27,
      100.0,
      1791.13,
      100.0
    ],
    "账面价值合计": [
      4142.16,
      100.0,
      3739.26,
      100.0,
      4013.96,
      100.0,
      1481.16,
      100.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30占比（%）",
      "2021.12.31金额",
      "2021.12.31占比（%）",
      "2020.12.31金额",
      "2020.12.31占比（%）",
      "2019.12.31金额",
      "2019.12.31占比（%）"
    ]
  },
  "297-1.xlsx": {
    "运输工具年限平均法": [
      4.0,
      3.0,
      24.25
    ],
    "title": [
      "折旧年限（年）",
      "预计残值率（%）",
      "年折旧率（%）"
    ]
  },
  "297-2.xlsx": {
    "运输设备年限平均法": [
      4.0,
      5.0,
      24.0
    ],
    "机器设备年限平均法": [
      5.0,
      5.0,
      19.0
    ],
    "title": [
      "折旧年限（年）",
      "预计残值率（%）",
      "年折旧率（%）"
    ]
  },
  "297-3.xlsx": {
    "房屋及建筑物年限平均法": [
      30.0,
      5.0,
      3.17
    ],
    "通用设备年限平均法": [
      5.0,
      5.0,
      19.0
    ],
    "专用设备年限平均法": [
      10.0,
      5.0,
      9.5
    ],
    "title": [
      "折旧年限（年）",
      "预计残值率（%）",
      "年折旧率（%）"
    ]
  },
  "298-2.xlsx": {
    "房屋及建筑物年限平均法": [
      20.0,
      5.0,
      4.75
    ],
    "机器设备年限平均法": [
      5.0,
      5.0,
      19.0
    ],
    "运输工具年限平均法": [
      5.0,
      5.0,
      19.0
    ],
    "title": [
      "折旧年限（年）",
      "预计残值率（%）",
      "年折旧率（%）"
    ]
  },
  "298-3_299-1.xlsx": {
    "在安装设备": [
      885.54,
      462.41,
      0.0,
      0.0
    ],
    "新厂房建设工程": [
      3920.87,
      269.76,
      0.0,
      0.0
    ],
    "医药港小镇办公楼四楼医学实验室洁净车间装修工程": [
      0.0,
      125.5,
      0.0,
      0.0
    ],
    "医药港小镇办公楼装修工程": [
      0.0,
      0.0,
      0.0,
      76.53
    ],
    "合计": [
      4806.41,
      857.67,
      0.0,
      76.53
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "299-2.xlsx": {
    "房屋及建筑物": [
      4322.56,
      687.56,
      0.0,
      3635.01
    ],
    "title": [
      "原值",
      "累计折旧",
      "减值准备",
      "账面价值"
    ]
  },
  "299-3.xlsx": {
    "土地使用权": [
      1951.46,
      87.2,
      1971.24,
      89.71,
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "办公软件": [
      286.42,
      12.8,
      226.16,
      10.29,
      182.65,
      100.0,
      90.03,
      100.0
    ],
    "账面原值合计": [
      2444.82,
      100.0,
      2331.58,
      100.0,
      235.81,
      100.0,
      107.17,
      100.0
    ],
    "累计摊销合计": [
      206.94,
      100.0,
      134.18,
      100.0,
      53.16,
      100.0,
      17.14,
      100.0
    ],
    "账面价值合计": [
      2237.88,
      100.0,
      2197.4,
      100.0,
      182.65,
      100.0,
      90.03,
      100.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30占比（%）",
      "2021.12.31金额",
      "2021.12.31占比（%）",
      "2020.12.31金额",
      "2020.12.31占比（%）",
      "2019.12.31金额",
      "2019.12.31占比（%）"
    ]
  },
  "300-1.xlsx": {
    "医药港小镇办公楼装修工程": [
      1552.17,
      1644.72,
      1832.3,
      0.0
    ],
    "医药港小镇办公楼三楼体外诊断试剂洁净车间装修工程": [
      266.69,
      282.69,
      0.0,
      0.0
    ],
    "医药港小镇办公楼西侧楼梯通道维修和食堂排污管道改造工程": [
      7.54,
      7.99,
      0.0,
      0.0
    ],
    "医药港小镇办公楼RT-PCR实验室改造工程": [
      7.56,
      8.02,
      0.0,
      0.0
    ],
    "医药港小镇办公楼抗体制备实验室改造工程": [
      9.01,
      0.0,
      0.0,
      0.0
    ],
    "医药港小镇办公楼四楼医学实验室洁净车间装修工程": [
      219.84,
      0.0,
      0.0,
      0.0
    ],
    "合计": [
      2062.81,
      1943.42,
      1832.3,
      0.0
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "300-2_301-1.xlsx": {
    "递延所得税资产资产减值准备": [
      232.78,
      140.1,
      65.81,
      23.9
    ],
    "递延所得税资产租赁的税会差异": [
      20.2,
      13.23,
      0.0,
      0.0
    ],
    "递延所得税资产收入的税会差异": [
      25.81,
      59.24,
      36.39,
      157.44
    ],
    "递延所得税资产尚未支付的职工薪酬": [
      64.4,
      35.27,
      29.86,
      4.9
    ],
    "科目递延收益": [
      23.79,
      33.23,
      52.12,
      0.0
    ],
    "科目可弥补亏损": [
      0.0,
      0.0,
      0.0,
      151.23
    ],
    "科目小计": [
      366.97,
      281.07,
      184.18,
      337.48
    ],
    "递延所得税负债交易性金融资产公允价值变动": [
      0.0,
      0.0,
      7.33,
      0.19
    ],
    "以净额列示的递延所得税资产合计": [
      366.97,
      281.07,
      176.85,
      337.28
    ],
    "title": [
      "",
      "",
      "",
      "单位：万元"
    ]
  },
  "301-2.xlsx": {
    "待验收无形资产": [
      200.91,
      220.86,
      14.15,
      0.0
    ],
    "预付设备款": [
      22.12,
      539.46,
      150.6,
      0.0
    ],
    "合计": [
      223.03,
      760.32,
      164.75,
      0.0
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "302-1.xlsx": {
    "流动负债": [
      7516.52,
      68.3,
      8137.51,
      68.9,
      9889.9,
      96.61,
      15444.79,
      100.0
    ],
    "非流动负债": [
      3489.33,
      31.7,
      3672.47,
      31.1,
      347.48,
      3.39,
      0.0,
      0.0
    ],
    "合计": [
      11005.84,
      100.0,
      11809.98,
      100.0,
      10237.38,
      100.0,
      15444.79,
      100.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30占比 （%）",
      "2021.12.31金额",
      "2021.12.31占比（%）",
      "2020.12.31金额",
      "2020.12.31占比（%）",
      "2019.12.31金额",
      "2019.12.31占比 （%）"
    ]
  },
  "302-2.xlsx": {
    "应付账款": [
      1373.61,
      18.27,
      929.79,
      11.43,
      1782.09,
      18.02,
      452.22,
      2.93
    ],
    "预收款项": [
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      5733.7,
      37.12
    ],
    "合同负债": [
      4129.04,
      54.93,
      4821.39,
      59.25,
      6504.51,
      65.77,
      0.0,
      0.0
    ],
    "应付职工薪酬": [
      1320.92,
      17.57,
      1845.81,
      22.68,
      1414.61,
      14.3,
      985.64,
      6.38
    ],
    "应交税费": [
      44.86,
      0.6,
      31.62,
      0.39,
      40.11,
      0.41,
      164.83,
      1.07
    ],
    "其他应付款": [
      231.55,
      3.08,
      149.26,
      1.83,
      148.57,
      1.5,
      8108.41,
      52.5
    ],
    "一年内到期的非流动负债": [
      416.54,
      5.54,
      359.64,
      4.42,
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "合计": [
      7516.52,
      100.0,
      8137.51,
      100.0,
      9889.9,
      100.0,
      15444.79,
      100.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30占比（%）",
      "2021.12.31金额",
      "2021.12.31占比 （%）",
      "2020.12.31金额",
      "2020.12.31占比 （%）",
      "2019.12.31金额",
      "2019.12.31占比 （%）"
    ]
  },
  "303-1.xlsx": {
    "设备工程款": [
      758.6,
      442.24,
      852.17,
      26.26
    ],
    "货款": [
      478.43,
      357.65,
      401.51,
      203.82
    ],
    "费用": [
      136.59,
      129.9,
      528.41,
      222.14
    ],
    "合计": [
      1373.61,
      929.79,
      1782.09,
      452.22
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "306-1.xlsx": {
    "工资、奖金、津贴和补贴": [
      813.77,
      1516.26,
      1187.92,
      909.86
    ],
    "职工福利费": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "社会保险费": [
      26.4,
      29.13,
      10.57,
      17.82
    ],
    "住房公积金": [
      1.23,
      1.38,
      0.0,
      0.17
    ],
    "工会经费和职工教育经费": [
      1.2,
      1.3,
      4.1,
      2.76
    ],
    "小计": [
      41.8,
      42.94,
      12.92,
      22.34
    ],
    "基本养老保险": [
      40.5,
      41.5,
      12.48,
      21.59
    ],
    "失业保险费": [
      1.3,
      1.44,
      0.44,
      0.75
    ],
    "辞退福利": [
      436.51,
      254.8,
      199.1,
      32.68
    ],
    "合计": [
      1320.92,
      1845.81,
      1414.61,
      985.64
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "306-2_307-1.xlsx": {
    "增值税": [
      1.69,
      0.0,
      0.0,
      120.78
    ],
    "企业所得税": [
      0.0,
      0.02,
      0.0,
      0.0
    ],
    "代扣代缴个人所得税": [
      18.75,
      31.2,
      39.68,
      28.8
    ],
    "城市维护建设税": [
      0.04,
      0.0,
      0.0,
      8.57
    ],
    "土地使用税": [
      5.01,
      0.0,
      0.0,
      0.0
    ],
    "教育费附加": [
      0.03,
      0.0,
      0.0,
      3.67
    ],
    "地方教育附加": [
      0.02,
      0.0,
      0.0,
      2.45
    ],
    "印花税": [
      0.2,
      0.4,
      0.43,
      0.55
    ],
    "残疾人就业保障金": [
      19.12,
      0.0,
      0.0,
      0.0
    ],
    "合计": [
      44.86,
      31.62,
      40.11,
      164.83
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "307-2.xlsx": {
    "押金保证金": [
      127.03,
      127.16,
      129.05,
      89.58
    ],
    "投资款": [
      0.0,
      0.0,
      0.0,
      8000.0
    ],
    "应付暂收款": [
      85.37,
      5.08,
      2.21,
      8.72
    ],
    "费用款": [
      19.15,
      17.02,
      17.31,
      10.11
    ],
    "合计": [
      231.55,
      149.26,
      148.57,
      8108.41
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "308-1.xlsx": {
    "租赁负债": [
      3330.74,
      95.46,
      3450.92,
      93.97,
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "递延收益": [
      158.59,
      4.54,
      221.55,
      6.03,
      347.48,
      100.0,
      0.0,
      0.0
    ],
    "合计": [
      3489.33,
      100.0,
      3672.47,
      100.0,
      347.48,
      100.0,
      0.0,
      0.0
    ],
    "title": [
      "2022.6.30金额",
      "2022.6.30占比（%）",
      "2021.12.31金额",
      "2021.12.31占比（%）",
      "2020.12.31金额",
      "2020.12.31占比（%）",
      "2019.12.31金额",
      "2019.12.31占比（%）"
    ]
  },
  "308-2.xlsx": {
    "股本": [
      36000.0,
      36000.0,
      36000.0,
      1500.0
    ],
    "资本公积": [
      12361.0,
      12223.51,
      7939.88,
      950.74
    ],
    "盈余公积": [
      849.68,
      849.68,
      156.37,
      48.69
    ],
    "其他综合收益": [
      -21.94,
      -7.4,
      -12.03,
      -20.02
    ],
    "未分配利润": [
      7467.39,
      6522.68,
      1300.54,
      375.25
    ],
    "归属于母公司股东权益": [
      56656.13,
      55588.47,
      45384.77,
      2854.65
    ],
    "少数股东权益": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "股东权益合计": [
      56656.13,
      55588.47,
      45384.77,
      2854.65
    ],
    "title": [
      "2022年 6月30日",
      "2021年 12月31日",
      "2020年 12月31日",
      "2019年 12月31日"
    ]
  },
  "309-1.xlsx": {
    "期初未分配利润": [
      6522.68,
      1300.54,
      375.25,
      -1893.73
    ],
    "加：本期归属于母公司股东的净利润": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "减：提取法定盈余公积": [
      0.0,
      693.31,
      156.37,
      48.69
    ],
    "整体变更设立股份公司": [
      0.0,
      0.0,
      3051.11,
      0.0
    ],
    "应付普通股股利": [
      0.0,
      900.0,
      0.0,
      0.0
    ],
    "期末未分配利润": [
      7467.39,
      6522.68,
      1300.54,
      375.25
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "309-2_310-1.xlsx": {
    "流动比率（倍）": [
      6.68,
      6.62,
      4.98,
      1.06
    ],
    "速动比率（倍）": [
      6.31,
      6.34,
      4.91,
      1.03
    ],
    "息税折旧摊销前利润 （万元）": [
      2238.44,
      9875.12,
      5378.21,
      3171.57
    ],
    "title": [
      "2022年 6月30日",
      "2021年 12月31日",
      "2020年 12月31日",
      "2019年 12月31日"
    ]
  },
  "310-2.xlsx": {
    "诺禾致源流动比率": [
      1.91,
      1.87,
      1.34,
      1.29
    ],
    "诺禾致源速动比率": [
      1.68,
      1.64,
      1.11,
      1.06
    ],
    "菲鹏生物流动比率": [
      -1.0,
      4.05,
      2.47,
      2.55
    ],
    "菲鹏生物速动比率": [
      -1.0,
      3.69,
      2.3,
      2.36
    ],
    "华大基因流动比率": [
      3.65,
      3.26,
      2.21,
      2.82
    ],
    "华大基因速动比率": [
      3.28,
      3.0,
      1.95,
      2.52
    ],
    "优宁维流动比率": [
      10.67,
      10.33,
      2.97,
      2.65
    ],
    "优宁维速动比率": [
      10.05,
      9.97,
      2.73,
      2.43
    ],
    "可比公司均值流动比率": [
      5.41,
      4.88,
      2.25,
      2.33
    ],
    "可比公司均值速动比率": [
      5.0,
      4.58,
      2.02,
      2.09
    ],
    "景杰生物流动比率": [
      6.68,
      6.62,
      4.98,
      1.06
    ],
    "景杰生物速动比率": [
      6.31,
      6.34,
      4.91,
      1.03
    ],
    "title": [
      "2022年 6月30日",
      "2021年 12月31日",
      "2020年 12月31日",
      "2019年 12月31日"
    ]
  },
  "311-1.xlsx": {
    "存货周转率": [
      0.82,
      2.45,
      4.82,
      4.73
    ],
    "应收账款周转率": [
      1.07,
      3.88,
      5.48,
      10.85
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "311-2_312-1.xlsx": {
    "诺禾致源存货周转率": [
      2.17,
      4.93,
      4.84,
      5.43
    ],
    "项目应收账款周转率": [
      1.48,
      4.39,
      4.32,
      5.62
    ],
    "菲鹏生物存货周转率": [
      -1.0,
      1.76,
      1.07,
      0.68
    ],
    "菲鹏生物应收账款周转率": [
      -1.0,
      8.35,
      7.78,
      3.23
    ],
    "华大基因存货周转率": [
      1.53,
      3.0,
      4.96,
      4.45
    ],
    "华大基因应收账款周转率": [
      2.5,
      4.88,
      6.01,
      2.26
    ],
    "优宁维存货周转率": [
      3.79,
      13.98,
      15.14,
      17.1
    ],
    "优宁维应收账款周转率": [
      1.6,
      4.41,
      3.5,
      4.06
    ],
    "可比公司均值存货周转率": [
      2.5,
      5.92,
      6.5,
      6.92
    ],
    "可比公司均值应收账款周转率": [
      1.86,
      5.51,
      5.4,
      3.79
    ],
    "景杰生物存货周转率": [
      0.82,
      2.45,
      4.82,
      4.73
    ],
    "景杰生物应收账款周转率": [
      1.07,
      3.88,
      5.48,
      10.85
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "313-1.xlsx": {
    "经营活动现金流入小计": [
      6516.16,
      20715.13,
      15348.25,
      13808.33
    ],
    "经营活动现金流出小计": [
      7948.97,
      16804.09,
      11219.96,
      9487.08
    ],
    "经营活动产生的现金流量净额": [
      -1432.81,
      3911.04,
      4128.29,
      4321.25
    ],
    "投资活动现金流入小计": [
      867.06,
      29676.47,
      56529.88,
      8020.04
    ],
    "投资活动现金流出小计": [
      4922.2,
      6248.66,
      82597.61,
      17497.69
    ],
    "投资活动产生的现金流量净额": [
      -4055.14,
      23427.82,
      -26067.73,
      -9477.64
    ],
    "筹资活动现金流入小计": [
      0.0,
      3519.77,
      30000.0,
      8000.0
    ],
    "筹资活动现金流出小计": [
      999.45,
      1579.32,
      0.0,
      1386.11
    ],
    "筹资活动产生的现金流量净额": [
      -999.45,
      1940.45,
      30000.0,
      6613.9
    ],
    "四、汇率变动对现金及现金等价物的影响": [
      17.18,
      -7.07,
      -17.18,
      4.2
    ],
    "五、现金及现金等价物净增加额": [
      -6470.22,
      29272.23,
      8043.38,
      1461.7
    ],
    "加：期初现金及现金等价物余额": [
      42523.51,
      13251.27,
      5207.89,
      3746.19
    ],
    "六、期末现金及现金等价物余额": [
      36053.28,
      42523.51,
      13251.27,
      5207.89
    ],
    "title": [
      "2022年 1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "314-1.xlsx": {
    "销售商品、提供劳务收到的现金": [
      5890.82,
      18512.12,
      14151.38,
      13593.97
    ],
    "收到的税费返还": [
      127.5,
      23.9,
      0.0,
      0.0
    ],
    "收到其他与经营活动有关的现金": [
      497.84,
      2179.11,
      1196.87,
      214.36
    ],
    "经营活动现金流入小计": [
      6516.16,
      20715.13,
      15348.25,
      13808.33
    ],
    "购买商品、接受劳务支付的现金": [
      1287.85,
      3374.98,
      2086.82,
      1099.44
    ],
    "支付给职工以及为职工支付的现金": [
      5381.42,
      8829.69,
      6018.32,
      5671.71
    ],
    "支付的各项税费": [
      267.49,
      1630.4,
      914.09,
      1035.35
    ],
    "支付其他与经营活动有关的现金": [
      1012.21,
      2969.02,
      2200.73,
      1680.59
    ],
    "经营活动现金流出小计": [
      7948.97,
      16804.09,
      11219.96,
      9487.08
    ],
    "经营活动产生的现金流量净额": [
      -1432.81,
      3911.04,
      4128.29,
      4321.25
    ],
    "title": [
      "2022年 1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "314-2_315-1.xlsx": {
    "净利润": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "加：资产减值准备": [
      662.88,
      527.65,
      291.79,
      72.49
    ],
    "固定资产折旧、油气资产折耗、生产性生物资产折旧": [
      693.11,
      1162.45,
      615.56,
      459.5
    ],
    "使用权资产折旧": [
      249.75,
      437.81,
      0.0,
      0.0
    ],
    "无形资产摊销": [
      72.76,
      81.02,
      36.02,
      14.25
    ],
    "长期待摊费用摊销": [
      123.19,
      188.18,
      46.9,
      0.0
    ],
    "处置固定资产、无形资产和其他长期资产的损失（收益以“－”号填列）": [
      0.0,
      -62.28,
      -7.55,
      0.0
    ],
    "固定资产报废损失（收益以“－”号填列）": [
      0.21,
      0.26,
      0.62,
      0.01
    ],
    "公允价值变动损失（收益以“－”号填列）": [
      0.0,
      0.0,
      -47.56,
      -1.29
    ],
    "财务费用（收益以“－”号填列）": [
      86.94,
      135.75,
      2.2,
      85.87
    ],
    "投资损失（收益以“－”号填列）": [
      0.0,
      -47.58,
      -222.33,
      -20.04
    ],
    "递延所得税资产减少（增加以“－”号填列）": [
      -85.9,
      -104.22,
      160.43,
      295.44
    ],
    "递延所得税负债增加（减少以“－”号填列）": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "存货的减少（增加以“－”号填列）": [
      -587.22,
      -1787.85,
      -401.71,
      134.81
    ],
    "经营性应收项目的减少（增加以“－”号填列）": [
      -3008.47,
      -2710.52,
      -3393.91,
      -1267.52
    ],
    "经营性应付项目的增加（减少以“－”号填列）": [
      -722.25,
      -1488.95,
      2525.7,
      2197.67
    ],
    "其他": [
      137.48,
      763.86,
      389.35,
      32.41
    ],
    "经营活动产生的现金流量净额": [
      -1432.81,
      3911.04,
      4128.29,
      4321.25
    ],
    "title": [
      "2022年 1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "316-1.xlsx": {
    "收回投资收到的现金": [
      0.0,
      29500.0,
      56000.0,
      8000.0
    ],
    "取得投资收益收到的现金": [
      0.0,
      96.43,
      222.33,
      20.04
    ],
    "处置固定资产、无形资产和其他长期资产收回的现金净额": [
      0.06,
      80.04,
      7.55,
      0.0
    ],
    "处置子公司及其他营业单位收到的现金净额": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "收到其他与投资活动有关的现金": [
      867.0,
      0.0,
      300.0,
      0.0
    ],
    "投资活动现金流入小计": [
      867.06,
      29676.47,
      56529.88,
      8020.04
    ],
    "购建固定资产、无形资产和其他长期资产支付的现金": [
      4922.2,
      5488.66,
      4947.61,
      1197.69
    ],
    "投资支付的现金": [
      0.0,
      0.0,
      77500.0,
      16000.0
    ],
    "取得子公司及其他营业单位支付的现金净额": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "支付其他与投资活动有关的现金": [
      0.0,
      760.0,
      150.0,
      300.0
    ],
    "投资活动现金流出小计": [
      4922.2,
      6248.66,
      82597.61,
      17497.69
    ],
    "投资活动产生的现金流量净额": [
      -4055.14,
      23427.82,
      -26067.73,
      -9477.64
    ],
    "title": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "317-1.xlsx": {
    "吸收投资收到的现金": [
      0.0,
      0.0,
      30000.0,
      8000.0
    ],
    "取得借款收到的现金": [
      0.0,
      0.0,
      0.0,
      0.0
    ],
    "收到其他与筹资活动有关的现金": [
      0.0,
      3519.77,
      0.0,
      0.0
    ],
    "筹资活动现金流入小计": [
      0.0,
      3519.77,
      30000.0,
      8000.0
    ],
    "偿还债务支付的现金": [
      0.0,
      0.0,
      0.0,
      500.0
    ],
    "分配股利、利润或偿付利息支付的现金": [
      0.0,
      900.0,
      0.0,
      36.11
    ],
    "支付其他与筹资活动有关的现金": [
      999.45,
      679.32,
      0.0,
      850.0
    ],
    "筹资活动现金流出小计": [
      999.45,
      1579.32,
      0.0,
      1386.11
    ],
    "筹资活动产生的现金流量净额": [
      -999.45,
      1940.45,
      30000.0,
      6613.9
    ],
    "title": [
      "2022年 1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ]
  },
  "337-2.xlsx": {
    "1.1研发中心": [
      17500.0,
      1500.0,
      2000.0,
      6125.0
    ],
    "1.2专家楼": [
      4000.0,
      1500.0,
      3000.0,
      1800.0
    ],
    "1.3地下建筑": [
      4300.0,
      2500.0,
      1000.0,
      1347.5
    ],
    "title": [
      "工程量（m2）",
      "土建单价 （元/m2）",
      "装修单价 （元/m2）",
      "投资额 （万元）"
    ]
  },
  "39-1.xlsx": {
    "邮政编码：": [
      310018.0
    ],
    "title": [
      "杭州景杰生物科技股份有限公司"
    ]
  },
  "44-1.xlsx": {
    "2020年 4月股权转让及增资1、股权转让 蒋旦如、程仲毅、赵雷杰、丁健、上海江村分别将其持有公司4.58%、1.49%、0.12%、0.57%、5.24%股权以1元/股的价格转让给杭州哲驰； 上海江村将其持有公司3.00%股权以1元/股的价格转让给杭州哲康； 蒋旦如、程仲毅、丁健、上海江村分别将其持有公司1.11%、0.44%、1.11%、2.21%股权以50元/股的价格转让给成都博远； 赵雷杰将其持有公司0.89%股权以50元/股的价格转让给翱鹰实业。 2、增资 公司注册资本由1500万元增至1660万元，新增注册资本160万元由新股东国投创业基金以8000万元认缴。原股东转让给杭州哲驰及杭州哲康的价格为1元/股，转让给成都博远和翱鹰实业的价格为50元/股；增资价格为50元/股": [
      1660.0
    ],
    "2020年 10月股权转让及增资1、股权转让 程仲毅将其持有公司0.48%和0.40%股权分别转让给苏州隆门六号和海南华昆； 蒋旦如将其持有公司1.00%和1.00%股权分别转让给苏州隆门六号和青岛正永； 丁健将其持有公司1.92%、0.60%和0.48%股权分别转让给达晨创鸿、福州泰弘和财智创赢； 杭州哲康将其持有公司0.80%、0.80%、0.60%和0.51%股权分别转让给国投创业基金、珠海泰弘、福州泰弘和苏州隆门六号； 翱鹰实业将其持有公司0.80%股权转让给浙江和信。 2、增资 公司注册资本由1660万元增至1859.20万元，新增注册资本由新股东珠海瑛杰、西藏数联、姜绪荣及原股东国投创业基金以人民币30000万元认缴，其中人民币199.20万元计入公司注册资本，剩余金额计入公司资本公积。杭州哲康转让给福州泰弘的价格为150.69元/股，翱鹰实业转让给浙江和信的价格为150.59元/股，丁健转让给福州泰弘的价格为150.51元/股，其余股权转让及增资价格均为150.60元/股": [
      1859.2
    ],
    "2020年 12月整体变更为股份公司以截至2020年10月31日的净资产账面价值，按1:0.8241的比例折合为股份公司的股份总额36000.00万股，整体变更为股份有限公司，全体股东持股比例不变": [
      0.0,
      36000.0
    ],
    "title": [
      "增资 /转让价格",
      "变动后注册资本/股本（万元）"
    ]
  },
  "48-1_49-1.xlsx": {
    "主要财务数据总资产（万元）": [
      623.51
    ],
    "主要财务数据净资产（万元）": [
      468.4
    ],
    "主要财务数据净利润（万元）": [
      -33.99
    ],
    "title": [
      "杭州景杰医学检验实验室有限公司"
    ]
  },
  "49-2.xlsx": {
    "主要财务数据总资产（万元）": [
      797.23
    ],
    "主要财务数据净资产（万元）": [
      14.51
    ],
    "主要财务数据净利润（万元）": [
      -82.66
    ],
    "title": [
      "上海臻至生物科技有限公司"
    ]
  },
  "50-1.xlsx": {
    "主要财务数据总资产（万元）": [
      538.62
    ],
    "主要财务数据净资产（万元）": [
      -326.36
    ],
    "主要财务数据净利润（万元）": [
      -68.83
    ],
    "title": [
      "PTM BIO LLC"
    ]
  },
  "73-1.xlsx": {
    "2020.01.01- 2020.03.19Yingming Zhao、吕松涛、金洪元、丁健": [
      0.0
    ],
    "title": [
      "具体情况"
    ]
  },
  "73-2_74-1.xlsx": {
    "2020.01.01- 2020.03.19赵纯梅、赵雷杰、贺铁明": [
      0.0
    ],
    "title": [
      "具体情况"
    ]
  },
  "74-2.xlsx": {
    "2020.01.01- 2020.12.22程仲毅经理": [
      0.0
    ],
    "title": [
      "具体情况"
    ]
  },
  "79-1.xlsx": {
    "薪酬总额": [
      209.284,
      389.96,
      428.45,
      192.62
    ],
    "利润总额": [
      1011.93,
      7917.32,
      4840.46,
      2614.73
    ],
    "title": [
      "2022年1-6月",
      "2021年",
      "2020年度",
      "2019年度"
    ]
  },
  "83-1.xlsx": {
    "第七年12%16%": [
      0.0
    ],
    "第八年12%16%": [
      0.0
    ],
    "第九年14%": [
      0.0,
      0.0
    ],
    "第十年14%": [
      0.0,
      0.0
    ],
    "title": [
      "不同服务年限对应的解锁比例（注2）二类（注4）",
      "不同服务年限对应的解锁比例（注2）三类（注5）"
    ]
  },
  "85-1.xlsx": {
    "2019年": [
      0.0,
      0.0
    ],
    "title": [
      "股份支付金额",
      "占公司当期归母净利润的比重"
    ]
  },
  "86-1.xlsx": {
    "员工人数": [
      310.0,
      326.0,
      269.0,
      217.0
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "87-2.xlsx": {
    "基本养老保险实际参保人数": [
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "基本医疗保险实际参保人数": [
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "工伤保险实际参保人数": [
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "失业保险实际参保人数": [
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "生育保险实际参保人数": [
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "住房公积金实际参保人数": [
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "title": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ]
  },
  "97-2.xlsx": {
    "蛋白质组学技术服务": [
      6754.56,
      75.63,
      17137.86,
      77.53,
      14308.07,
      93.22,
      11028.78,
      95.11
    ],
    "蛋白质组分析": [
      3683.44,
      41.24,
      8952.01,
      40.5,
      6459.71,
      42.09,
      5637.92,
      48.62
    ],
    "蛋白质修饰组分析": [
      3071.12,
      34.38,
      8185.85,
      37.03,
      7848.36,
      51.14,
      5390.87,
      46.49
    ],
    "抗体试剂产品": [
      2177.06,
      24.37,
      4966.32,
      22.47,
      1040.18,
      6.78,
      566.52,
      4.89
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "title": [
      "2022年1-6月金额",
      "2022年1-6月比例（%）",
      "2021年金额",
      "2021年比例（%）",
      "2020年金额",
      "2020年比例（%）",
      "2019年金额",
      "2019年比例（%）"
    ]
  }
}